Protox Therapeutics Inc. (“Protox”, TSX: PRX), a developer of innovative products for the treatment of urological diseases, today announced that it has entered into a US $15 million loan agreement ...

Canada's Protox Therapeutics has landed a $75 million development and commercialization agreement with Japan-based Kissei Pharmaceutical. The $75 million deal covers PRX302, Protox's PSA-activated pro ...

Protox Therapeutics Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease VANCOUVER, April 29 /CNW/ - Protox ...

Protox Therapeutics Inc. is appointing William Rohn and Amit Sobti to the company’s board of directors. “We are delighted to welcome Bill and Amit to help guide Protox through the exciting phase of ...

Below are three under the radar stocks from the healthcare sector that I have been following for the past 3-6 months which have upcoming catalysts in the form of expected strategic deals, clinical ...

PRX302 is currently in North American Phase II evaluation as PSA-activated pore-punching prodrug. Kissei Pharamaceutical is paying Protox Therapeutics $3 million up front for exclusive Japanese rights ...

Shareholders of Vancouver-based Protox Therapeutics Inc. (TSX:PRX) have approved multi-stage financing that could see a global private equity firm become the company’s majority shareholder. Under the ...

It's not easy keeping a poker face. I mean there are so many times when I meet people and it would be beneficial to keep a straight face, but sometimes it's just so hard! When a patient tells me they ...

VANCOUVER, June 2 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo ...

VANCOUVER – Protox Therapeutics Inc. (TSX:PRX), a developer of drugs to treat urological diseases, said Monday it has entered into a US $15 million loan agreement with a U.S. lender to help the ...